ClinicalTrials.gg
TerminatedNCT01986348KINGUpdated Jan 26, 2023Results posted

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

A Phase 2 interventional study of Selinexor in Glioblastoma and Glioma, sponsored by Karyopharm Therapeutics Inc. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up)

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
227th of 1,155
76 · median 33
Started
2014
with 53 others
Phase 2
396 of 1,302
37 open now
Registered
599th of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 227th largest by enrollment of the 1,155 interventional ones that give a count, is one of 54 that started in 2014, is one of 396 in phase 2, and was the 599th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.

Read the detailed description

This is an open-label, multicenter, Phase 2 study to evaluate the efficacy and safety of oral selinexor in participants with recurrent gliomas.

Initially, the study included 2 arms: an exploratory Surgical Arm (Arm A) with sequential enrollment for participants who require surgery and a medical arm (Arm B) for participants who are not eligible for surgery.

Enrollment in Arm B was stopped to explore alternative dosing in Protocol Versions ≥ 4.0 to potentially improve tolerability. Four arms (Arms C, D, E, and F) were added to the Medical Arm in Protocol Version 4.0. Arms E and F were eliminated in protocol version 6.0 and no participants were ever enrolled in these arms.

Participants in the primary population enrolled under Protocol Version ≥ 4.0 will be randomized to Arm C and Arm D (approximately 30 participants per arm) to explore alternative dosing to potentially improve tolerability.

After screening and registration/randomization in the study, participants enrolling in Arm A or randomized to Arm C will receive 60 mg selinexor orally twice weekly. Participants randomized to Arm D will receive 80 mg selinexor orally weekly.

Participants will be treated until progression of disease or the development of unacceptable toxicities. All participants will then undergo the End of Treatment (EOT) visit.

03

Conditions studied

  • Glioblastoma
  • Glioma

Keywords

  • GBM
  • Glioblastoma
  • selinexor
  • KPT-330
  • Karyopharm
  • brain tumor
  • brain cancer
  • Glioma
  • Astrocytoma
  • Oligodendrogliomas
  • Oligo-astrocytomas
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed GBM (including all histologic variants) at first diagnosis with radiographic evidence of recurrent disease after treatment with radiotherapy and temozolomide;
  • 18 years of age or older
  • Participants enrolling in the medical arm (Arms B, C and D) must be on a stable or decreasing dose of (or none) for at least 5 days prior to the baseline MRI;
  • (according to RANO guidelines)
  • Surgical arm (Arm A) must be predicted pre-operatively to have sufficiently sized tumor to be resected and provide tissue samples for exploratory assessments.

Exclusion criteria

Exclusion Criteria:

  • Markedly decreased visual acuity if attributed to other causes than GBM.
  • Known active hepatitis A, B, or C
  • Participants with coagulation problems and medically significant bleeding in the month prior to start of treatment (e.g., peptic ulcer, epistaxis, spontaneous bleeding). Prior history of DVT or PE is not exclusionary.
  • Participants must not have significantly diseased or obstructed gastrointestinal tract, malabsorption, uncontrolled vomiting or diarrhea, or inability to swallow oral medications.
  • Prior treatment with bevacizumab or other direct VEGF/ VEGFR inhibitors. For any question of the definition of a direct VEGF/VEGFR inhibitor, consult Sponsor.
  • Arms C and D only: body surface area \< 1.2 m².
  • \< 24 days from prior temozolomide, \< 6 weeks from nitrosourea, \< 4 weeks from other chemotherapy or agents prior to start of treatment within study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Arm A: Selinexor 60 mg and Surgery

    Participants who required surgery received up to 3 doses of oral selinexor tablets 60 milligrams (mg) twice weekly (BIW) on Day 1, Day 3 and between 2 and 48 hours prior to surgery, subsequently underwent surgery for resection of their tumor and resumed selinexor tablets 60 mg BIW after recovery, during Week 1 to 4 of each 4-week cycle, until progression of disease (PD) or development of unacceptable toxicities.

    Drug: Selinexor

  • Experimental
    Arm B: Selinexor 50 mg/m^2

    Participants who were not eligible for surgery received selinexor tablets 50 mg per square meter (mg/m\^2) BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.

    Drug: Selinexor

  • Experimental
    Arm C: Selinexor 60 mg

    Participants who were not eligible for surgery received selinexor tablets 60 mg BIW during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.

    Drug: Selinexor

  • Experimental
    Arm D: Selinexor 80 mg

    Participants who were not eligible for surgery received selinexor tablets 80 mg once weekly (QW) during Week 1 to 4 of each 4-week cycle until PD or development of unacceptable toxicities.

    Drug: Selinexor

Interventions

  • One cycle is 28 days (4 weeks).

    Also known as: KPT-330

06

What researchers measure

Primary outcomes

  1. 6-Month Progression-Free Survival (PFS) Rate

    The analysis of 6mPFS was performed by calculating the estimated survival probability of having PFS ≥ 6 months based on Kaplan-Meier method, where PFS was defined as the time from the start of study treatment until first documented progression based on Response Assessment in Neuro-Oncology (RANO) criteria, or death from any cause. Progressive disease occurs when either of the criteria was present: greater than or equal to (≥) 25 percentage (%) increase in T1 gadolinium enhancing disease, increase in T2/ Fluid-attenuated inversion recovery (FLAIR), detection of new lesions, or decreased clinical status.

    Time frame: From start of study treatment up to disease progression or death, whichever occurred first (assessed up to Month 6)

Secondary outcomes

  1. Overall Response Rate (ORR)

    The ORR was determined as percentage of participants who had either complete response (CR) or partial response (PR) using the RANO criteria. CR: No T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, no corticosteroid use and stable, or increasing clinical status. PR: ≥50% decrease in T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, stable or decreased use of corticosteroids, and stable or increased clinical status.

    Time frame: Up to 71 months

  2. Overall Survival (OS)

    The OS was calculated from the date of start of study treatment to the date of death. Participants who were still alive prior to the data cut-off for final efficacy analysis, or who dropout prior to study end, were censored on the day they were last known to be alive. The OS was estimated using Kaplan-Meier method.

    Time frame: From date of study treatment up to date of death (assessed up to 71 months)

  3. Progression-free Survival (PFS)

    The PFS was calculated from the date of start of study treatment to the date of disease progression based on RANO criteria, or date of death should progression not have occurred. Progressive disease occurs when either of the criteria was present: ≥25% increase in T1 gadolinium enhancing disease, increased T2/FLAIR, detection of new lesions, or decreased clinical status.

    Time frame: From start of study treatment up to disease progression (assessed up to 71 months)

  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was defined as an AE that was fatal; life threatening (places the participant at immediate risk of death); requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; and other important medical events. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the Investigator through the end of the study. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of study treatment administration up to 71 months

07

Results

Posted Aug 2, 2021
Limitations and caveats
Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up).

Participant flow

This study was conducted at 6 sites across the United States of America, Denmark and Netherland between 03 March 2014 and 23 January 2020.

Participant flow — Overall Study
MilestoneArm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
Started8241430
Completed0000
Not completed8241430
Withdrew: Death8221021
Withdrew: Lost to follow-up0002
Withdrew: Physician decision0001
Withdrew: Progressive disease0020
Withdrew: Withdrawal by participant0121
Withdrew: Study terminated by sponsor0003
Withdrew: Other-unspecified0102

Outcome measures

Primary6-Month Progression-Free Survival (PFS) Rate

The analysis of 6mPFS was performed by calculating the estimated survival probability of having PFS ≥ 6 months based on Kaplan-Meier method, where PFS was defined as the time from the start of study treatment until first documented progression based on Response Assessment in Neuro-Oncology (RANO) criteria, or death from any cause. Progressive disease occurs when either of the criteria was present: greater than or equal to (≥) 25 percentage (%) increase in T1 gadolinium enhancing disease, increase in T2/ Fluid-attenuated inversion recovery (FLAIR), detection of new lesions, or decreased clinical status.

Time frame:
From start of study treatment up to disease progression or death, whichever occurred first (assessed up to Month 6)
Reported as:
Number · percentage of participants
6-Month Progression-Free Survival (PFS) Rate
percentage of participantsArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
6-Month Progression-Free Survival (PFS) Rate9.72 (2.67 to 35.39)7.69 (1.17 to 50.57)17.24 (7.77 to 38.27)
SecondaryOverall Response Rate (ORR)

The ORR was determined as percentage of participants who had either complete response (CR) or partial response (PR) using the RANO criteria. CR: No T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, no corticosteroid use and stable, or increasing clinical status. PR: ≥50% decrease in T1 gadolinium enhancing disease, stable or decreasing T2/FLAIR, no new lesions, stable or decreased use of corticosteroids, and stable or increased clinical status.

Time frame:
Up to 71 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
Overall Response Rate (ORR)8.3 (1.0 to 27.0)7.7 (0.2 to 36.0)10.0 (2.1 to 26.5)
SecondaryOverall Survival (OS)

The OS was calculated from the date of start of study treatment to the date of death. Participants who were still alive prior to the data cut-off for final efficacy analysis, or who dropout prior to study end, were censored on the day they were last known to be alive. The OS was estimated using Kaplan-Meier method.

Time frame:
From date of study treatment up to date of death (assessed up to 71 months)
Reported as:
Median · months
Overall Survival (OS)
monthsArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
Overall Survival (OS)10.51 (4.93 to 16.95)8.48 (7.29 to NA)10.15 (7.03 to 15.38)
SecondaryProgression-free Survival (PFS)

The PFS was calculated from the date of start of study treatment to the date of disease progression based on RANO criteria, or date of death should progression not have occurred. Progressive disease occurs when either of the criteria was present: ≥25% increase in T1 gadolinium enhancing disease, increased T2/FLAIR, detection of new lesions, or decreased clinical status.

Time frame:
From start of study treatment up to disease progression (assessed up to 71 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
Progression-free Survival (PFS)1.64 (1.18 to 3.15)1.87 (1.84 to 14.88)1.87 (1.81 to 3.02)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) was defined as an AE that was fatal; life threatening (places the participant at immediate risk of death); requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; and other important medical events. TEAE was defined as any AE with onset or worsening of a pre-existing condition on or after the first administration of study medication through 30 days following last dose or any event considered drug-related by the Investigator through the end of the study. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of study treatment administration up to 71 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsArm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
Participants with TEAEs8241430
Participants with TESAEs5777

Adverse events

Collected over From start of study treatment administration up to 71 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Selinexor 60 mg and Surgery8/8 (100%)5/8 (62.5%)8/8 (100%)
Arm B: Selinexor 50 mg/m^222/24 (91.7%)7/24 (29.2%)24/24 (100%)
Arm C: Selinexor 60 mg10/14 (71.4%)7/14 (50%)14/14 (100%)
Arm D: Selinexor 80 mg21/30 (70%)7/30 (23.3%)30/30 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventArm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
SeizureNervous system disorders0/81/243/142/30
DiarrhoeaGastrointestinal disorders1/80/240/140/30
Meningitis bacterialInfections and infestations1/80/240/140/30
Staphylococcal infectionInfections and infestations1/80/240/140/30
Decreased appetiteMetabolism and nutrition disorders1/80/240/140/30
Cerebrospinal fluid leakageNervous system disorders1/80/240/140/30
Cerebrovascular accidentNervous system disorders1/80/240/140/30
PneumocephalusNervous system disorders1/80/240/140/30
Confusional statePsychiatric disorders1/80/240/140/30
EmbolismVascular disorders1/80/240/140/30
Most frequent other events
Showing 10 of 120
Most frequent other events
EventArm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mg
FatigueGeneral disorders5/819/2411/1416/30
ThrombocytopeniaBlood and lymphatic system disorders6/816/246/1411/30
NauseaGastrointestinal disorders6/812/249/1421/30
Decreased appetiteMetabolism and nutrition disorders3/812/2410/148/30
Gait disturbanceGeneral disorders5/85/243/143/30
ConstipationGastrointestinal disorders3/88/247/147/30
HyponatraemiaMetabolism and nutrition disorders4/811/243/141/30
HeadacheNervous system disorders4/85/246/145/30
LeukopeniaBlood and lymphatic system disorders0/87/241/1414/30
VomitingGastrointestinal disorders1/89/245/1413/30

Baseline characteristics

Safety population consisted of all participants who had received any amount of study treatment.

Age, Continuous
Age, Continuous(Years)Arm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mgTotal
Mean56.6 ± 6.7051.1 ± 13.0449.5 ± 12.3654.3 ± 11.9852.7 ± 11.99
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mgTotal
Female1551122
Male71991954
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mgTotal
Hispanic or Latino00033
Not Hispanic or Latino82082460
Unknown or Not Reported046313
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Selinexor 60 mg and SurgeryArm B: Selinexor 50 mg/m^2Arm C: Selinexor 60 mgArm D: Selinexor 80 mgTotal
American Indian or Alaska Native00000
Asian00011
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White82482565
More than one race00000
Unknown or Not Reported006410
08

Study locations

6 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute, Center for Neuro-Oncology
    Boston, Massachusetts 02215, United States
  • Columbia University, Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
  • The Phase I Unit, Dept. of Oncology, Rigshospitalet
    Copenhagen, DK-2100, Denmark
  • University of Groningen Faculty of Medical Sciences, Medical Oncology
    Groningen, 9713 GZ, Netherlands
  • Erasmus MC-Daniel den Hoed Cancer Center- Neuro-Oncology Unit
    Rotterdam, 3008AE, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2014 to primary completion in Jan 2020, 70 months.

Results were first posted in Aug 2021, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2013
First posted
Nov 18, 2013
StartActual
Mar 3, 2014
Primary completionActual
Jan 23, 2020
CompletionActual
Jan 23, 2020
Results first posted
Aug 2, 2021
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01986348
Responsible party
Sponsor
First posted
Nov 18, 2013
Start date
Mar 3, 2014
Primary completion
Jan 23, 2020
Completion
Jan 23, 2020
Results posted
Aug 2, 2021
Last update
Jan 26, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion